Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging...

Full description

Bibliographic Details
Main Authors:	Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stintzing, Matthias Ocker
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Cells
Subjects:	fibroblast growth factor receptor amplification mutation fusion FGFR inhibitor predictive biomarker
Online Access:	https://www.mdpi.com/2073-4409/11/19/3180

Similar Items

Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
by: Alexandru Nita, et al.
Published: (2021-06-01)

FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
by: Csongor G. Lengyel, et al.
Published: (2022-01-01)

Molecular Confirmation of G1138A Mutation in FGFR gene in Achondroplasia
by: Shyam Bahadur Khanal, et al.
Published: (2018-06-01)

Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer
by: Seonggyu Byeon, et al.
Published: (2023-11-01)

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor
by: Daniel Barmas-Alamdari, et al.
Published: (2024-01-01)

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
by: Yohei Chiba, et al.
Published: (2022-08-01)

Correlation between different FGFR1 mutations and congenital hypogonadotropic hypogonadism
by: YANG Yufan, WANG Xi, NIE Min, WU Xueyan, MAO Jiangfeng
Published: (2023-05-01)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
by: Leomar Y. Ballester, et al.
Published: (2019-04-01)

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
by: Maxim Noeraparast, et al.
Published: (2024-10-01)

FGFR1 is a potential therapeutic target in neuroblastoma
by: Flora Cimmino, et al.
Published: (2022-04-01)

Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma
by: Elena I. Fomchenko, et al.
Published: (2021-02-01)

Recombinant expression in E. coli of human FGFR2 with its transmembrane and extracellular domains
by: Adam Bajinting, et al.
Published: (2017-06-01)

Psychomotor Delay in a Child with FGFR3 G380R Pathogenic Mutation Causing Achondroplasia
by: Mahmut C. Ergoren, et al.
Published: (2021-05-01)

Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models
by: Syeda Afshan, et al.
Published: (2024-09-01)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
by: Narisa Dewi Maulany Darwis, et al.
Published: (2022-05-01)

The prevalence of Fibroblast Growth Factor Receptor 1 Gene (FGFR1) amplification in Non-Small Cell Lung Cancer (NSCLC) by Real-time PCR
by: Sanaz Homayounfar, et al.
Published: (2025-10-01)

Genetic variants of FGFR family associated with height, hypertension, and osteoporosis
by: Hye-Won Cho, et al.
Published: (2023-01-01)

18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging
by: Yang Chen, et al.
Published: (2023-04-01)

Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family
by: Muhammad Ajmal, et al.
Published: (2017-07-01)

FGFR3–TACC3: A novel gene fusion in cervical cancer
by: Benedito A. Carneiro, et al.
Published: (2015-08-01)

Molecular analysis of exon 7 of the fibroblast growth factor receptor 2 (FGFR2) gene in an Indonesian patient with Apert syndrome: a case report
by: Gara Samara Brajadenta, et al.
Published: (2019-08-01)

Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma
by: Katherine A. Lawson‐Michod, et al.
Published: (2022-10-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability
by: Reiri Sono, et al.
Published: (2024-12-01)

Mutation spectrum of Kallmann syndrome: identification of five novel mutations across ANOS1 and FGFR1
by: Guoming Chu, et al.
Published: (2023-03-01)

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
by: Kazumasa Komura, et al.
Published: (2023-11-01)

Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4
by: You-Lu Pan, et al.
Published: (2018-03-01)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
by: Andrew J. Weickhardt, et al.
Published: (2022-05-01)

Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
by: Jinhao Chen, et al.
Published: (2025-03-01)

Activated FGFR3 suppresses bone regeneration and bone mineralization in an ovariectomized mouse model
by: Itaru Kawashima, et al.
Published: (2023-03-01)

A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis
by: Yanran Bi, et al.
Published: (2024-01-01)

GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression
by: Maria Francesca Santolla, et al.
Published: (2019-03-01)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01)

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
by: Leisl M. Packer, et al.
Published: (2019-04-01)

Fibroblast growth factor receptor 4 (FGF4) and fibroblast growth factor 19 (FGFR19) autocrine enhance brest cancer cells survival
by: Tiong, Kai Hung, et al.
Published: (2016)

Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection
by: Magdalena Lipok, et al.
Published: (2019-05-01)

The Evaluation of <i>FGFR1</i>, <i>FGFR2</i> and <i>FOXO1</i> in Orofacial Cleft Tissue
by: Jana Goida, et al.
Published: (2022-04-01)

Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
by: Maria P. Kotini, et al.
Published: (2020-12-01)

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions
by: Douglas A. Mata, et al.
Published: (2020-11-01)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
by: Gregor Vlacic, et al.
Published: (2019-09-01)